Takeda Pharmaceutical (TAK) Non-Current Assets (2017 - 2026)

Takeda Pharmaceutical has reported Non-Current Assets for 10 years, with the latest figure at $78.5 billion in Q2 2026.

• On a quarterly basis, Non-Current Assets fell 1.15% year-over-year to $78.5 billion in Q2 2026; TTM through Jun 2026 was $78.5 billion, a 1.15% decrease from a year earlier, with the FY2026 full-year figure at $79.2 billion, up 2.88% from the prior year.
• Non-Current Assets was $78.5 billion for Q2 2026 at Takeda Pharmaceutical, down from $79.2 billion in the prior quarter.
• The five-year high for Non-Current Assets was $91.1 billion in Q1 2022, with the low at $76.9 billion in Q1 2025.
• Average Non-Current Assets over 5 years is $82.5 billion, with a median of $80.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets declined 14.12% in 2022, then grew 3.33% in 2023.
• Over 5 years, Non-Current Assets stood at $77.2 billion in 2022, then climbed by 3.33% to $79.8 billion in 2023, then rose by 1.83% to $81.3 billion in 2024, then retreated by 1.7% to $79.9 billion in 2025, then retreated by 1.71% to $78.5 billion in 2026.
• The last three Non-Current Assets figures came in at $78.5 billion (Q2 2026), $79.2 billion (Q1 2026), and $79.9 billion (Q4 2025), per Business Quant data.